(SDZ) Sandoz - SW
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: SW (Switzerland) | Market Cap: 29.285m CHF | Total Return: 57.7% in 12m
Avg Turnover: 37.2M
Rev. Trend: 31.6%
Qual. Beats: 0
Warnings
Fakeout
Tailwinds
Confidence
Sandoz Group AG is a Switzerland-based pharmaceutical company specializing in the development and commercialization of generic medicines and biosimilars. Headquartered in Basel, the firm maintains a global presence across diverse therapeutic areas, including oncology, immunology, and cardiovascular health, while also producing active pharmaceutical ingredients (APIs).
The generic drug industry operates on a high-volume business model aimed at increasing healthcare accessibility by providing lower-cost alternatives once original patents expire. Biosimilars represent a more complex segment of this market, requiring sophisticated manufacturing processes to replicate large-molecule biological drugs rather than simple chemical structures.
Investors can further evaluate these market dynamics and company fundamentals by reviewing the detailed metrics available on ValueRay.
- Biosimilar pipeline expansion drives high-margin revenue growth
- Generic drug price erosion pressures European market margins
- Strategic manufacturing investments improve long-term operating leverage
- Post-spin-off cost optimization programs accelerate EBITDA margin expansion
| Net Income: 918.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 3.38 > 1.0 |
| NWC/Revenue: 11.37% < 20% (prev 16.38%; Δ -5.01% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.59b > Net Income 918.7m |
| Net Debt (4.33b) to EBITDA (1.85b): 2.34 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (437.5m) vs 12m ago 1.23% < -2% |
| Gross Margin: 47.19% > 18% (prev 47.30%; Δ -0.12% > 0.5%) |
| Asset Turnover: 53.27% > 50% (prev 45.82%; Δ 7.45% > 0%) |
| Interest Coverage Ratio: 6.05 > 6 (EBIT TTM 1.34b / Interest Expense TTM 221.0m) |
| A: 0.06 (Total Current Assets 8.16b - Total Current Liabilities 6.89b) / Total Assets 22.0b |
| B: 0.31 (Retained Earnings 6.83b / Total Assets 22.0b) |
| C: 0.06 (EBIT TTM 1.34b / Avg Total Assets 21.0b) |
| D: 0.74 (Book Value of Equity 9.38b / Total Liabilities 12.6b) |
| Altman-Z'' = 2.60 = A |
| DSRI: 0.72 (Receivables 2.77b/3.15b, Revenue 11.2b/9.12b) |
| GMI: 1.00 (GM 47.30% / 47.19%) |
| AQI: 0.99 (AQ_t 0.50 / AQ_t-1 0.51) |
| SGI: 1.22 (Revenue 11.2b / 9.12b) |
| TATA: -0.03 (NI 918.7m - CFO 1.59b) / TA 22.0b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at CHF 67.92 with a total of 1,951,217 shares traded.
Over the past week, the price has changed by +1.31%,
over one month by +4.08%,
over three months by +12.33% and
over the past year by +57.67%.
Sandoz has no consensus analysts rating.
Market Cap USD = 36.6b (29.3b CHF * 1.2511 CHF.USD)
P/E Trailing = 40.7711
P/E Forward = 18.9753
P/S = 2.6705
P/B = 3.9913
P/EG = 0.8952
Revenue TTM = 11.2b USD
EBIT TTM = 1.34b USD
EBITDA TTM = 1.85b USD
Long Term Debt = 4.70b USD (from longTermDebt, last quarter)
Short Term Debt = 673.0m USD (from shortTermDebt, last quarter)
Debt = 6.07b USD (from shortLongTermDebtTotal, last quarter) + Leases 385.0m
Net Debt = 4.33b USD (calculated: Debt 6.07b - CCE 1.74b)
Enterprise Value = 41.0b USD (36.6b + Debt 6.07b - CCE 1.74b)
Interest Coverage Ratio = 6.05 (Ebit TTM 1.34b / Interest Expense TTM 221.0m)
EV/FCF = 50.58x (Enterprise Value 41.0b / FCF TTM 810.0m)
FCF Yield = 1.98% (FCF TTM 810.0m / Enterprise Value 41.0b)
FCF Margin = 7.25% (FCF TTM 810.0m / Revenue TTM 11.2b)
Net Margin = 8.22% (Net Income TTM 918.7m / Revenue TTM 11.2b)
Gross Margin = 47.19% ((Revenue TTM 11.2b - Cost of Revenue TTM 5.90b) / Revenue TTM)
Gross Margin QoQ = 48.43% (prev 45.79%)
Tobins Q-Ratio = 1.86 (Enterprise Value 41.0b / Total Assets 22.0b)
Interest Expense / Debt = 3.64% (Interest Expense 221.0m / Debt 6.07b)
Taxrate = 24.27% (294.5m / 1.21b)
NOPAT = 1.01b (EBIT 1.34b * (1 - 24.27%))
Current Ratio = 1.18 (Total Current Assets 8.16b / Total Current Liabilities 6.89b)
Debt / Equity = 0.65 (Debt 6.07b / totalStockholderEquity, last quarter 9.38b)
Debt / EBITDA = 2.34 (Net Debt 4.33b / EBITDA 1.85b)
Debt / FCF = 5.34 (Net Debt 4.33b / FCF TTM 810.0m)
Total Stockholder Equity = 8.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.38% (Net Income 918.7m / Total Assets 22.0b)
RoE = 10.58% (Net Income TTM 918.7m / Total Stockholder Equity 8.68b)
RoCE = 10.00% (EBIT 1.34b / Capital Employed (Equity 8.68b + L.T.Debt 4.70b))
RoIC = 6.64% (NOPAT 1.01b / Invested Capital 15.3b)
WACC = 7.98% (E(36.6b)/V(42.7b) * Re(8.84%) + D(6.07b)/V(42.7b) * Rd(3.64%) * (1-Tc(0.24)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.01 | Cagr: 0.78%
[DCF] Terminal Value 77.97% ; FCFF base≈510.0m ; Y1≈584.6m ; Y5≈860.4m
[DCF] Fair Price = 19.92 (EV 12.9b - Net Debt 4.33b = Equity 8.62b / Shares 432.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 31.60 | Revenue CAGR: 5.83% | SUE: 0.05 | # QB: 0
EPS current Year (2026-12-31): EPS=4.11 | Chg30d=-1.49% | Revisions=+65% | GrowthEPS=+13.0% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=4.65 | Chg30d=-1.22% | Revisions=+53% | GrowthEPS=+13.1% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +65%